The positive Phase 3 result therefore provides clinical validation, at the level of RFS and DMFS, of a strategy combining individualized neoantigen-directed immunotherapy with established PD-1 blockade. It is important, however, not to extend the current findings beyond what the trial has demonstrated. INTerpath-001 establishes efficacy endpoints in resected high-risk cutaneous melanoma. It does not […]